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Abstract
Endocrine resistance is a major problem with anti-estrogen treatments and how to overcome resistance is a major concern
in the clinic. Reliable measurement of cell viability, proliferation, growth inhibition and death is important in screening for
drug treatment efficacy in vitro. This report describes and compares commonly used proliferation assays for induced
estrogen-responsive MCF-7 breast cancer cell cycle arrest including: determination of cell number by direct counting of
viable cells; or fluorescence SYBRHGreen (SYBR) DNA labeling; determination of mitochondrial metabolic activity by 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay; assessment of newly
synthesized DNA using 5-ethynyl-29-deoxyuridine (EdU) nucleoside analog binding and Alexa FluorH azide visualization
by fluorescence microscopy; cell-cycle phase measurement by flow cytometry. Treatment of MCF-7 cells with ICI 182780
(Faslodex), FTY720, serum deprivation or induction of the tumor suppressor p14ARF showed inhibition of cell proliferation
determined by the Trypan Blue exclusion assay and SYBR DNA labeling assay. In contrast, the effects of treatment with ICI
182780 or p14ARF-induction were not confirmed using the MTS assay. Cell cycle inhibition by ICI 182780 and p14ARF-
induction was further confirmed by flow cytometric analysis and EdU-DNA incorporation. To explore this discrepancy
further, we showed that ICI 182780 and p14ARF-induction increased MCF-7 cell mitochondrial activity by MTS assay in
individual cells compared to control cells thereby providing a misleading proliferation readout. Interrogation of p14ARF-
induction on MCF-7 metabolic activity using TMRE assays and high content image analysis showed that increased
mitochondrial activity was concomitant with increased mitochondrial biomass with no loss of mitochondrial membrane
potential, or cell death. We conclude that, whilst p14ARF and ICI 182780 stop cell cycle progression, the cells are still viable
and potential treatments utilizing these pathways may contribute to drug resistant cells. These experiments demonstrate
how the combined measurement of metabolic activity and DNA labeling provides a more reliable interpretation of cancer
cell response to treatment regimens.
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Introduction
Drug resistance is a major problem in cancer research. As a
result there is an increasing emphasis on understanding the
mechanism of drug metabolism in the control of cancer cell
proliferation, viability and death to enable improved drug
therapies for patients. A major interest in our laboratory is to
understand anti-estrogen treatment resistance in breast cancer.
We have been using three methods to inhibit estrogen action:
anti-estrogen ICI 182780 (Faslodex); inhibition of sphingosine
kinase activation of the estrogen receptor using the immunosup-
pressive drug FTY720; re-activation of the tumor suppressor
p14ARF-p53 pathway. Faslodex is currently in clinical use as an
anti-hormone therapy and also commonly used in the laboratory
to study estrogen action [1]. This compound binds and down-
regulates the estrogen receptor (ER) and induces quiescence by
stopping cell cycle progression from G0/G1 into S-phase [2].
The drug FTY720 is a sphingosine analogue and is currently in
clinical use as an immunosuppressant for multiple sclerosis [3].
FTY720 acts by inhibiting sphingosine kinase (SK) activity [4].
SK1 is causally associated with endocrine resistance, in part, by
enhancing estrogenic proliferative activity [5]. FTY720 has been
shown to directly affect mitochondria and trigger apoptosis [6].
Mimetics of p14ARF, such as nutlin 3, which activate the p53
pathway, are now in clinical trial for cancer therapy [7]. It is well
documented that p14ARF binds to hdm2 (homolog of mouse
mdm2) and stabilizes p53 protein thus inhibiting cell cycle
progression [8]. Importantly for our research, p14ARF is
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20623
associated with anti-estrogen action whereby both mdm2 and
p53 bind to the estrogen receptor (ER) and inhibit estrogen
activity in breast cancer cells [9,10,11]. In our hands p14ARF
inhibits cell proliferation and induces hypertrophy in MCF-7
cells.
Assays commonly used by cancer researchers to assess cell
number, cell viability and cytotoxicity in response to drug
treatment include the metabolic MTT [12] or MTS [13] assays
that measure mitochondrial enzymatic activity that occurs only in
viable, proliferating cells. However, cell cycle arrest does not
necessarily result in metabolic dysfunction. In some instances a
perturbation of cellular processes resulting in increased metabolic
activity can provide a false positive readout of cell response to
treatment [14]. Alkylators and anthracyclines, for example,
damage proteins as well as DNA, resulting in energy-dependent
protein degradation and resynthesis. An alternative approach to
determining cell cycle arrest utilizes DNA labeling with SYBRH
Green I (SYBR) or other dyes such as CyQuant, whereby DNA
content can be accurately measured by fluorescence spectrometry
[15,16,17,18]. This assay more accurately measures cell number,
proliferation and cell cycle arrest as analyzed by DNA content.
The EdU click-IT assay is designed to measure only proliferating
cells in live cell culture. Newly synthesized DNA incorporates
5-ethynyl-29-deoxyuridine (EdU) nucleoside analog, similar to the
BrdU assay, but less toxic.
In this study we examine the reliability of MTS, SYBR-DNA
labeling and EdU in vitro assays to determine cell cycle arrest in
estrogen sensitive MCF-7 cells following treatment with ICI
182780, FTY720 or following the induction of p14ARF. We
discuss the practical advantages/disadvantages of using mitochon-
drial activity assays and DNA labeling assays in parallel as fast,
effective methods of screening anti-proliferative effects following
drug intervention to determine cell fate. Furthermore, under-
standing the mechanism of drug action at the cellular or nuclear
level will aid in the design of combinatorial drug therapies for
patients with unmet needs.
Results
Comparative analysis of Cell counts, MTS and SYBR-DNA
labeling assays
In this study we analyzed the anti-proliferative effects of the
pure anti-estrogen ICI 182780, p14ARF-p53 induction, FTY720
drug treatment and serum starvation in MCF-7 cells. These
experiments were conducted with MCF-7 cells showing p14ARF
induction with IPTG. Without IPTG induction, these MCF-7 cells
retained all the characteristics of native breast cancer cells
including their responsiveness to anti-estrogen treatment (unpub-
lished data). We compared viability of cells post-treatment using
the Trypan Blue exclusion assay measured by direct cell counts,
the MTS assay by colorimetric measurement, and SYBR-DNA
assay measured by cell fluorescence. For simplicity we expressed
the results as a mean percentage of control 6 SE to allow for
direct comparison of all assays (Fig. 1).
Induction of p14ARF with IPTG. As shown in Figure 1
(IPTG), induction of p14ARF with IPTG dramatically inhibited
cell proliferation by 60–80% (cell counts) within the first 2 days
compared to control cells when a 20–50% reduction was
observed by SYBR green fluorescent assay. Interestingly, the
MTS assay showed an increase in mitochondrial activity at 24 h
(115%) and the activity was only suppressed by 10% at day 2
despite a significant reduction in cell number. The SYBR assay
showed an 85% inhibition in proliferation by day 3, yet the MTS
assay showed only 20% suppression in metabolic activity. The
trypan blue count confirmed that viable cell numbers did not
increase in the IPTG condition when compared to the controls
(Fig. 1, IPTG).
ICI 182780 treatment. Upon treatment with the anti-estrogen ICI
182780 the SYBR green assay showed a deficit of 20% and MTS
assay showed little change within the first 2 days despite a 30–
50% reduction in cell number (Fig. 1, ICI 182780). Similar to
IPTG results, when cells were treated with ICI 182780 the SYBR
assay showed a marked inhibition of proliferation (60%) by day 3,
whereby the MTS assay only showed 20% suppression in
mitochondrial activity. The trypan blue count confirmed the
number of viable cells did not increase compared to control
(Fig. 1, ICI 182780).
FTY720 treatment. When cells were treated with FTY720, all
three assays, Trypan blue counts, SYBR and MTS assays showed
70–80% suppression in proliferation by day 3 (Fig. 1, FTY720).
However, in contrast, the FTY720 treatment significantly reduced
mitochondrial activity (MTS) on day 1 (40% of control) with little
impact on SYBR DNA content (Fig. 1, FTY720). This result is
consistent with previous reports showing FTY720 directly slows
mitochondrial activity [6].
Serum free treatment. When cells were deprived of serum
there was no difference in results yielded from the Trypan Blue,
MTS or SYBR assays (Fig. 1, Serum free).
Comparatively, when assessing the different treatment regimes,
our results showed that the MTS and SYBR assays might not be as
reliable a measure of cell proliferation as cell counts.
Flow cytometric analysis of ICI 182780 or p14ARF
anti-proliferative effects
The above observations showed distinct discrepancies between
the MTS and SYBR-DNA assay readouts and cell counts when
cells were treated with ICI 182780 and IPTG (induction of
p14ARF) at days 1 and 2. Flow cytometric analysis confirmed cell
cycle inhibition post treatment with ICI 182780 or IPTG (Fig. 2),
concordant with the cell count results (Fig. 1). Flow cytometric
results presented additional information on cell behaviour post
drug treatment; IPTG induction of p14ARF significantly reduced
the S-phase peak with an accumulation of cells in the G1 and
G2/M cell-cycle phases whereas ICI 182780-treated cells accu-
mulated in the G1/GO phase (Fig. 2A). These experiments were
repeated with three different p14ARF-clonal cell lines with
similar results to ensure that G2/M accumulation post-IPTG
treatment was not due to aberrant clonal variation (Fig. 2B). Our
results are consistent with the published literature, which
demonstrate ICI 182780 induces quiescence (G1/G0) in MCF-7
cells [2], and p14ARF-p53 arrests cells in both G1 and G2/M
cell-cycle phases [19].
EdU-DNA incorporation post-treatment with ICI 182780
and IPTG (p14ARF)
To measure DNA synthesis, in particular the percentage of
cells in S-phase, EdU was added directly to the MCF-7p14ARF
cell culture medium 24 h and 96 h post-treatment with IPTG or
ICI 182780 and cells were incubated for a further 20 h. This
allowed the visualization of individual cell proliferation captured
over a 20-hour window. At 24 h post-IPTG treatment, 5% of
IPTG-treated cells synthesized DNA (Fig. 3), suggesting rapid
repression of DNA synthesis upon reactivation of the p14ARF
pathway in MCF-7 cells, which is consistent with the cell count
data, but not with MTS or SYBR green assays (Fig. 1). Reduced
proliferation was maintained for 96 h–116 h (Fig. 3). These
later-day results were in agreement with the cell counts and
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SYBR-DNA assay as shown in Figure 1, but not with the MTS
assay. ICI 182780-treated cells showed a significant inhibition in
DNA synthesis by day 4–5 post-treatment when only 20% of
these cells incorporated EdU when compared to control cells
(P,0.0001; Fig. 3). Interestingly, ICI 182780 treatment showed
a delayed cell cycle arrest mechanism when compared to
p14ARF induction with IPTG, which showed an early inhibition
of DNA synthesis by day 1–2 (P,0.0001; Fig. 3). This is
consistent with the Flow analysis data and previously reported
literature where ICI 182780 effective blocks the cell cycle only in
G1/G0 phase [2].
P14ARF and ICI 182780 increase mitochondrial activity in
MCF-7 cells
We have shown significant differences between the MTS and
SYBR assay readouts when investigating the anti-proliferative effect
of ICI 182780 and p14ARF-induction. We therefore determined
mitochondrial activity on a cell-cell basis using the MTS assay. On
day 3 post-treatment with ICI 182780, IPTG or control, cells were
harvested and equal numbers of treated and untreated cells were
seeded into 96 well plates and mitochondrial activity determined by
MTS assay (Fig. 4). On a comparative cell-cell basis IPTG-treated
Figure 1. Comparative analysis of MCF-7 cell viability, cell number and mitochondrial activity. Cells were treated with 5 mM IPTG, 10 nM
ICI 182780, 5 mM FTY720, or serum deprived (serum free) 48 h post-seeding. Using the Trypan Blue exclusion method cells were harvested and viable
cells counted using a haemocytometer at days indicated. MTS and SYBR-DNA assays were performed, as detailed in materials and methods, at days
indicated. The treatment results are shown as a percentage of the uninduced vehicle control (6SE) correlating with viable cell number (Trypan blue
counts), colorimetric measurement (MTS), and fluorescent intensity (SYBR assay). Each experiment was performed in triplicate at least 3 times with
similar results.
doi:10.1371/journal.pone.0020623.g001
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cells showed a significant (2.6 fold) increase in mitochondrial activity
compared to untreated cells (P,0.0001; Fig. 4B). ICI 182780 also
resulted in a significantly increased mitochondrial activity (1.6 fold)
per cell (P,0.0001; Fig. 4A).
Induction of p14ARF increases mitochondrial biomass
with no loss of mitochondrial membrane potential
To understand the mechanism underlying the increased
metabolic activity in MCF-7 cells with p14ARF induction,
mitochondrial content and the mitochondrial membrane potential
in treated and untreated cells were analysed. At day 3 post-IPTG-
treatment, MitoTrackerTM red, CellTrackerTM green, and
Hoechst 33342 was added to the cell cultures and live cells were
imaged (Fig. 5A). A noticeable increase in cell size by day 3 was
observed concomitant with an increase in mitochondria density
per cell; this increase in cell size is consistent with the senescence-
phenotype. Mitochondria cell number was quantified using the
BD pathway Bioimager and Attovision software (Fig. 5B). A 3-fold
increase (P,0.001) in mitochondrial counts post-p14ARF induc-
tion compared to control cells was observed.
Measurement of mitochondrial membrane potentiality
(DYmt). Tetramethylrhodamine ethyl ester (TMRE) is a red-
orange fluorescent dye, which is readily taken up by active
mitochondria. The amount of orange/red fluorescence is
indicative of DYmt. To determine whether the mitochondria in
our studies were functional we used TMRE uptake as a measure of
DYmt. IPTG treated cells showing an increased TMRE
incorporation at day 3 compared to untreated (TMRE-control)
cells (P,0.001), confirmed that DYmt was significantly increased
in p14ARF expressing cells (Fig. 5 C and D), consistent with an
increased biomass of functional mitochondria. These results
strongly support the conclusion that the increase in metabolic
activity, as demonstrated by MTS assays, was due to an increase in
the numbers of functional mitochondria.
Discussion
Large scale screening of drug effects on cell fate in cell culture
is an important initial step to determine their potential efficacy in
clinical application. Two screening assays commonly used to
assess cell proliferation are the MTS assay, which measures
dehydrogenase enzyme activity found in metabolically active
cells, and SYBR-DNA labelling to determine DNA content. This
study highlights the pitfalls researchers encounter by relying on
one or both methods to determine cell viability or proliferation.
Although we showed that SYBR-DNA is generally a more
reliable, reproducible method to assess the anti-proliferative
activity of drugs compared to the MTS assay over time, there are
distinct discrepancies at early time points (days 1–2) between
SYBR-green assay readouts and cell counts. In contrast, we
clearly showed that the MTS assay is not always a reliable
method to detect cell proliferation and is dependent on the drug
of interest mode of action.
Nevertheless, each method can provide valuable information on
drug efficacy. Here we show that initial screening using both
methodologies offers some insight in cell behavior and presents a
more informative picture of cell fate post drug treatment.
Specifically, in this report we showed that the MTS assay is not
on its own trustworthy as a method to measure the anti-
proliferative activity of ICI 182780 which is clinically used for
the treatment of advanced breast cancer [20], nor is it a reliable
method to assess the anti-proliferative capacity of p14ARF-p53, an
important tumor suppressor pathway. Although both treatments
inhibit cell proliferation, we showed that the cells do not die and,
indeed, showed increased metabolic activity.
Using p14ARF-induction as an example, SYBR-DNA labeling
correlates favorably over time with viable cell number estimation
by the Trypan Blue exclusion viable cell assay. Parallel studies
using the MTS assay again indicated that although cells expressing
p14ARF cells stopped proliferating, the viability of the cells was
not strongly impacted. In fact, as with ICI 182780 treatment there
was a clear increase in the metabolic activity of these cells.
Information gained from Flow cytometric analyses of the cell-
cycle-parameters and EDU live cell labeling provides additional
insight on cell behaviour dependent on drug treatments. Inhibition
of cell proliferation by p14ARF and ICI 182780 clearly showed
different modes of action of cell-cycle phase repression, potentially
contributing to latent recurrence or irreversible inhibition of cell
proliferation post-drug treatment.
One of the major problems with current breast cancer
treatments is the high rate of resistance to current therapy. For
example, hormone therapies such as ICI 182780 used to treat
Figure 2. Flow cytometric analysis of cell cycle phases post ICI 182780 and IPTG treatment. Cells were treated with 10 nM ICI 182780 or
5 mM IPTG (p14ARF-induction) 48 h post seeding. At 48 h post-treatment cells were harvested, stained with propidium iodide solution as described
in materials and methods and analysed for cell cycle distribution by flow cytometry using Modfit software. A. Fluorescence histograms showing cell
cycle distribution of control, IPTG and ICI 182780 treated MCF-7 cells (representative experiment). B. Representative column graph showing the
percentage of cells (6 SD) in each cell cycle. This experiment was performed three times with three different cell lines showed similar results.
doi:10.1371/journal.pone.0020623.g002
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breast cancer could also be called cytostatic therapy. Drug
treatments such as ICI 182780 potentially contribute to latent
resistant breast cancer, as we have shown cells retain viability and
are metabolically active post-treatment. Further support for this
idea is provided by our previous results showing that estrogen and
progestins can reverse the anti-estrogenic effects of ICI 182780 in
culture [21]. Drugs that target alternative signaling pathways, such
as FTY720, may prove to be more effective alone, or in
combinational therapies, in obtaining controlled cell death and
tumor regression. Initial high throughput screening combining
metabolic activity assays with DNA-labeling and Flow cytometric
analyses would provide more reliable preliminary interpretation of
Figure 3. EdU incorporation post ICI 182780 and IPTG (p14ARF) treatment. Cells were seeded on cover slips and treated with 5 mM IPTG or
10 nM ICI 182780 24 h post-seeding. EdU was added to the medium on days 1 and 4 and cells were incubated for a further 20 h. EdU incorporation
was visualized by staining with Alexafluor 488 (green). The nucleus was stained with Hoechst 33342 (blue) and images were taken on a Nikon
fluorescence microscope (magnification6200). Column graph shows % cells staining for EdU compared to Hoechst 33342 stained nuclei (6 SE).
Experiments were performed in triplicate (duplicate biological experiments). A minimum of 500 cells was counted for each treatment.
doi:10.1371/journal.pone.0020623.g003
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cell reactions to drug regimens and also benefit the identification
and design of novel therapeutic drug combination therapies.
Materials and Methods
Cell lines and culture conditions
MCF-7 epithelial breast cancer cells (ATCC 30–4500K) were
maintained in complete medium: DMEM supplemented with 10%
fetal bovine serum and penicillin/streptomycin. MCF-7 cells were
stably transfected with p14ARF (MCF-7p14ARF) using the IPTG
inducible system (Stratagene) as previously described [22]. Cells
were maintained in hygomycin B (200 mg/mL and geneticin
(200 mg/mL). Expression of p14ARF was induced by adding
5 mM IPTG to the cell medium and incubated at 37uC. Addition
of 10 nM ICI 182780 (Faslodex) (Santa Cruz Biotechnology, Inc)
and 5 mM FTY720 (Cayman Chemicals, Michigan, USA) were
used to induce cell cycle arrest. All cells were tested mycoplasma
free using the mycoAlert Kit (Lonza, Australia).
Cell proliferation assays
MTS assay 1. Cells were seeded in 96-well plates at a density
of 500 cells/well (dependent on the cell line) in 50 mL medium and
left to attach for 48 h at 37uC. Subsequently, cells were exposed to
drugs in an additional 50 mL medium. The first lane and column
contained medium only to negate edge effects due to evaporation
of the medium, the second lane was untreated controls (no drug).
Cultures were further incubated at 37uC after which cells were
assayed with MTS at time intervals 1–3 days as indicated.
Measurements were made in accordance with the manufacturers
instructions (Promega Corp., Madison, WI). In brief, 100 mL MTS
reagent was added directly to the wells and cells incubated at 37uC
for a minimum of 2 h. Assessment of metabolic activity was
recorded as relative colorimetric changes measured at 492 nm.
The data was transferred to Microsoft Excel and analyzed.
Background absorbance was corrected using triplicate sets of wells
containing medium only (no cells) and MTS reagent as per
experimental well. The results represent the mean 6 SE of
quadruple samples, expressed as a percentage of control. Each
experiment was performed at least three times.
MTS assay 2. Cells were seeded in 6-well plates at a density of
105 cells/well and treated with drug concentrations as indicated or
5 mM IPTG (to induce p14ARF expression). At time intervals, as
indicated, cells were trypsinized, counted using a haemocytometer
and an equal number of cells were added to a 96-well plate. MTS
reagent was added to the cells and incubated at 37uC for a
minimum of 2 h and analyzed as described above.
SYBR-DNA-labeling assay. The SYBR-DNA-labeling ex-
periment was performed as described for the MTS assay 1. Assays
were stopped at time intervals 1–3 days post treatment as indicated,
by flicking off the medium and freezing the plate. Relative cell
numbers were determined in a similar manner to the CyQuant
assay (Invitrogen); cells were stained with 200 mL/well of SYBRH
Green I (Invitrogen) 1:4000 in a hypotonic lysis buffer (10 mM Tris
HCl pH 8, 5 mM EDTA, 0.1% Triton X-100) for 4–7 days in the
dark at 4uC and then quantified by flourimetry at 535 nm with
485 nm excitation, measured using a Wallac VICTOR3V plate
reader (Perkin Elmer P/L Melbourne Vic, Australia). Treated cell
fluorescence intensity was presented as a percentage of intensity of
control cells.
Trypan Blue exclusion viable cell assay. Cells were tryp-
sinized and resuspended in equal volumes of medium and Trypan
blue (0.05% solution) and counted using a haemocytometer.
Trypan blue dye (Invitrogen) exclusion was used to assess cell
viability.
Click iTTM EdU Imaging Kit. The EdU (5-ethynyl-29
-deoxyuridine) is a nucleoside analog of thymidine that is
incorporated into DNA only during DNA synthesis allowing the
visualization of newly synthesized DNA [23]. This imaging
technology is a less toxic alternative to the BrdU incorporation
assay. To perform the assay cells were plated on cover slips in 6-
well plates and incubated at 37uC for 24 h before treatment with
5 mM IPTG, 10 nM ICI 182780, or 5 mM FTY720. At time
intervals indicated cells were treated with 2.5 mM EdU, directly
added to the culture medium, and incubated for a further 20 h at
Figure 4. ICI 182780 and p14ARF increase mitochondria activity. Cells were treated with 10 nM ICI 182780 (A) or 5 mM IPTG (B), 48 h post
seeding. At 72 h post treatment cells were counted (see inset) and equal number of cells plated in 96 well plates. Mitochondrial activity was
measured using the MTS assay. Treatment results were presented as percentage of control (6 SE) in column graphs. Each experiment was performed
in duplicate at least 3 times.
doi:10.1371/journal.pone.0020623.g004
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37uC to ensure capture of the majority of proliferating cells.
Following EdU addition for 20 h, cells were fixed with 4%
paraformaldehyde and permeabilised using acetone for 5 min at
220uC. Incorporation of EdU was observed by incubating fixed
cells with 2% BSA in PBS for 30 m and Alexa fluor 488 for a
further 30 min under Cu(I)-catalyzed click reaction conditions, as
described by the manufacturer. Cells were washed with PBS, and
counterstained with Hoechst 33342 (1:1000) in PBS before
mounting on slides using Fluor mount (Sigma) for fluorescent
microscopy.
Cell kinetic studies. Cells were seeded at 105 per well in 6
well plates and treated with 10 nM ICI 182780, 5 mM IPTG or
vehicle, 24 h post-seeding. Cell cycle distribution was assessed
using flow cytometry as described previously [21]. Briefly, at 48 h
post-treatment cells were harvested, washed with PBS, fixed in
cold ethanol and stained with propidium iodide solution
containing RnaseA. A. Flow cytometric analysis was performed
on a FACSCalibur (Becton Dickinson) using Modfit LT analysis
software (Verity Software House, Inc., Topsham, ME). A
minimum of 20,000 cells was counted for each sample. Analysis
was done with ModFit software.
Mitochondria detection. Cells were treated with IPTG or
vehicle over a period of 3 days. Live cell cultures were incubated
with MitoTrackerH 50 nM (Invitrogen) as per manufacturer
instructions Cells were imaged using phase contrast and
fluorescence microscopy using an Eclipse Ti-U inverted
fluorescent microscope (Nikon, Tokyo, Japan) with a 5 mega-
pixel cooled camera (6400 magnification). Mitochondrial counts,
size, and distribution were measured using Pathway BioimagerTM
analyzed with Attovision software (6200 magnification).
Mitochondrial membrane potential. The DYmt was mea-
sured by flow cytometry using with 488 nm excitation and 670 nm
emission. Log scale fluorescence histograms were analyzed for
median relative fluorescent unit (RFU) intensity using Flow Jo
software.
Statistical analyses. All data were analysed by the Students
t-test using Microsoft Excel, unless otherwise stated.
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Figure 5. Induction of p14ARF increases mitochondrial biomass and maintains membrane potential. A. Cells were treated with 5 mM
IPTG 48 h post-seeding. At day 3 post-IPTG treatment, live cells were incubated with Mitotracker (red), CellTracker (green) and Hoechst 33342 (blue)
and imaged using an inverted fluorescent microscope (magnification6400). Cells treated with IPTG noticeably increased in size. B. Images processed
by high content imaging (magnification6200) and mitochondria (per cell) counted using BD AttovisionTM software. C. Cells were treated with 5 mM
IPTG 48 h post-seeding. On day 3 post-IPTG-treatment cells were stained with TMRE for 15 min (+), or left unstained (2) and run through a flow
cytometer (IPTG=black, control =white). TMRE-IPTG-treated cells showed increased fluorescence intensity compared to the TMRE-control cells, which
is indicative of an increase in DYmt in IPTG-treated cells. D. The median FL2 relative fluorescence units (RFU) of control and IPTG treated cells (day 3)
were determined by flow cytometry. The column graph shows the median RFU of TMRE-stained cells minus unstained cells (6SE). This experiment
was performed at least twice in triplicate.
doi:10.1371/journal.pone.0020623.g005
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